FDA approves Eli Lilly Alzheimer's drug, expanding treatment options in U.S.

The Food and Drug Administration approved Eli Lilly's Alzheimer's drug donanemab, expanding the limited treatment options for the mind-wasting disease. Donanemab and a similar treatment called Leqembi from Biogen and Eisai are milestones in the treatment of Alzheimer's after three decades of failed efforts to develop medicines that can fight the fatal disease. for adults over 65, according to the Alzheimer's Association.

It's a long-awaited win for Eli Lilly after donanemab faced obstacles in its path to market. The FDA rejected the drug's approval last year due to insufficient data, then surprisinglyEli Lilly's drug is now the third of its kind to reach the market after Leqembi and an ill-fated therapy from Biogen and Eisai called Aduhelm. The two companies recently dropped that medicine.

Donanemab and Leqembi are milestones in the treatment of Alzheimer's after three decades of failed efforts to develop medicines that can fight the fatal disease. Both drugs are monoclonal antibodies that target toxic plaques in the brain called amyloid, a hallmark of Alzheimer's, to slow the progression of the disease in patients at the early stages of it. Neither treatment is a cure.

Three patients who took Eli Lilly's drug in a late-stage trial died from severe forms of those side effects, called amyloid-related imaging abnormalities, or ARIA.Pfizer struggles to regain faith with Wall Street, employees after Covid decline

Health Health Latest News, Health Health Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

FDA analysis raises no major concerns about Eli Lilly Alzheimer's drugAn FDA analysis of trial data for Eli Lilly's experimental Alzheimer's drug donanemab released on Thursday revealed no red flags, but raised questions about safety of the treatment for patients with early-stage disease.
Source: KSLcom - 🏆 549. / 51 Read more »

FDA advisors recommend Eli Lilly Alzheimer’s drug that slows diseaseEli Lilly's new Alzheimer's drug, donanemab, received approval from an advisory panel for the FDA. The full agency is expected to approve the drug by spring.
Source: dcexaminer - 🏆 6. / 94 Read more »

Alzheimer’s drug from Eli Lilly wins backing of FDA committeeAn advisory committee to the Food and Drug Administration found the drug was safe and effective at slowing the progression of the disease, setting the stage for the agency to approve it.
Source: washingtonpost - 🏆 95. / 72 Read more »

FDA approves Eli Lilly's Alzheimer’s drug that slows memory declineBerkeley Lovelace Jr. is a health and medical reporter for NBC News. He covers the Food and Drug Administration, with a special focus on Covid vaccines, prescription drug pricing and health care. He previously covered the biotech and pharmaceutical industry with CNBC.
Source: NBCNewsHealth - 🏆 707. / 51 Read more »